ACM
COGT icon

Atika Capital Management’s Cogent Biosciences COGT Stock Holding History

Atika Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Sell
293,200
-212,800
-42% -$7.86M 1.42% 20
2025
Q4 		$18M Buy
+506,000
New +$14.2M 1.89% 12

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atika Capital Management's COGT Position: Q1 2026 in Review

Atika Capital Management reduced its Cogent Biosciences (COGT) stake by 42% in Q1 2026, selling an estimated $7.86M and leaving 293,200 shares worth $11.3M. The position accounts for 1.42% of the portfolio, ranked #20.

Atika Capital Management first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. The position peaked at $18M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Atika Capital Management held 293,200 shares of Cogent Biosciences worth $11.3M as of Q1 2026.
  • Atika Capital Management sold 212,800 Cogent Biosciences shares in Q1 2026, an estimated $7.86M.
  • Cogent Biosciences made up 1.42% of Atika Capital Management's portfolio in Q1 2026, its #20 holding.
  • Atika Capital Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Atika Capital Management's Cogent Biosciences position peaked at $18M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.